Accord Healthcare Ltd and another v Astellas Pharma GmbH and another

Patent – Medicine. The Chancery Division made declarations as sought by the claimant pharmaceutical companies. It held that the initial marketing authorisation for a drug, Ribomustin, had been obtained in 2005, as contended by the claimants, rather than 2010, as contended by the defendant pharmaceutical companies. As a result, the ten-year period of delay before the claimants could market their own product had commenced in 2005, not 2010.

Category: